
Mitchell D Creinin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/463228/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mifepristone prior to osmotic dilators for dilation and evacuation cervical preparation: A randomized, double-blind, placebo-controlled pilot study. Contraception, 2022, 107, 23-28.	0.8	1
2	Society of Family Planning Committee statement on IUD nomenclature. Contraception, 2022, 106, 1-2.	0.8	4
3	Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Review of Clinical Pharmacology, 2022, 15, 121-137.	1.3	33
4	Mechanism of action of a 0.075 mg norgestrel progestogen-only pill 2. Effect on cervical mucus and theoretical risk of conception. Contraception, 2022, 112, 43-47.	0.8	5
5	Mechanism of action of norgestrel 0.075 mg a progestogen-only pill. I. Effect on ovarian activity. Contraception, 2022, 112, 37-42.	0.8	5
6	Future Pregnancy Considerations after Premature Birth of an Infant Requiring Intensive Care: A Qualitative Study. Women's Health Issues, 2022, 32, 484-489.	0.9	1
7	Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use. American Journal of Obstetrics and Gynecology, 2022, 227, 871.e1-871.e7.	0.7	12
8	Recommendations for standardization of bleeding data analyses in contraceptive studies. Contraception, 2022, 112, 14-22.	0.8	9
9	Management of Cesarean Scar Ectopic Pregnancies at an Academic Referral Center [A82]. Obstetrics and Gynecology, 2022, 139, 24S-25S.	1.2	Ο
10	Twelve-month prescribing of contraceptive pill, patch, and ring before and after a standardized electronic medical record order change. Contraception, 2021, 103, 60-63.	0.8	4
11	Conception rates in women desiring pregnancy after levonorgestrel 52Âmg intrauterine system (Liletta®) discontinuation. Contraception, 2021, 103, 26-31.	0.8	8
12	Medication Abortion With Pharmacist Dispensing of Mifepristone. Obstetrics and Gynecology, 2021, 137, 613-622.	1.2	22
13	Pharmacists' knowledge, perspectives, and experiences with mifepristone dispensing for medication abortion. Journal of the American Pharmacists Association: JAPhA, 2021, 61, 785-794.e1.	0.7	7
14	Relationship of parity and prior cesarean delivery to levonorgestrel 52 mg intrauterine system expulsion over 6 years. Contraception, 2021, 103, 444-449.	0.8	7
15	Assessing the Pregnancy Protective Impact of Scheduled Nonadherence to a Novel Progestin-Only Pill: Protocol for a Prospective, Multicenter, Randomized, Crossover Study. JMIR Research Protocols, 2021, 10, e29208.	0.5	3
16	US referral center experience removing nonpalpable and difficult contraceptive implants with in-office ultrasonography: A case series. Contraception, 2021, 103, 428-430.	0.8	6
17	Coronavirus disease 2019 impact on abortion care at a Northern California tertiary family planning program. American Journal of Obstetrics and Gynecology, 2021, 225, 94-95.	0.7	3
18	Standardizing abortion research outcomes (STAR): Results from an international consensus development study. Contraception, 2021, 104, 484-491.	0.8	7

#	Article	IF	CITATIONS
19	Ethinyl estradiol and levonorgestrel patch phase 3 data clarification. Contraception, 2021, 104, 216.	0.8	0
20	SATISFACTION WITH THE SEGESTERONE ACETATE AND ETHINYL ESTRADIOL CONTRACEPTIVE VAGINAL SYSTEM AMONG PREVIOUS ORAL CONTRACEPTIVE OR CONTRACEPTIVE VAGINAL RING USERS. Fertility and Sterility, 2021, 116, e290.	0.5	0
21	Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception, 2021, 104, 222-228.	0.8	36
22	Contraceptive plans before pre-operative assessment and at procedure in surgical abortion patients. Contraception, 2021, , .	0.8	0
23	Comparing preoperative dating and postoperative dating for second-trimester surgical abortions. Contraception, 2020, 101, 5-9.	0.8	2
24	Bleeding changes after levonorgestrel 52-mg intrauterine system insertion for contraception in women with self-reported heavy menstrual bleeding. American Journal of Obstetrics and Gynecology, 2020, 222, S888.e1-S888.e6.	0.7	14
25	Mifepristone Antagonization With Progesterone to Prevent Medical Abortion. Obstetrics and Gynecology, 2020, 135, 158-165.	1.2	28
26	Six-year contraceptive efficacy and continued safety of a levonorgestrel 52†mg intrauterine system. Contraception, 2020, 101, 159-161.	0.8	11
27	How to combine dual aims of reducing population growth and a rights-based noncoercive approach - In reply. Contraception, 2020, 102, 141.	0.8	0
28	Progestin-only pill use over 6Âmonths postpartum. Contraception, 2020, 102, 251-253.	0.8	2
29	In Reply. Obstetrics and Gynecology, 2020, 135, 970-971.	1.2	0
30	Oral contraceptive generations $\hat{a} \in$ Time to stop using a marketing myth to define nomenclature. Contraception, 2020, 102, 143-144.	0.8	10
31	Contraception across the transmasculine spectrum. American Journal of Obstetrics and Gynecology, 2020, 223, 945-946.	0.7	1
32	Best Practices for Counseling Adolescents about the Etonogestrel Implant. Journal of Pediatric and Adolescent Gynecology, 2020, 33, 448-454.	0.3	19
33	Family planning, population growth, and the environment. Contraception, 2020, 101, 145-147.	0.8	8
34	Gabapentin for pain management after osmotic dilator insertion and prior to dilation and evacuation: A randomized controlled trial. Contraception, 2020, 101, 167-173.	0.8	7
35	Management of early pregnancy loss with mifepristone and misoprostol: clinical predictors of treatment success from a randomized trial. American Journal of Obstetrics and Gynecology, 2020, 223, 551.e1-551.e7.	0.7	22
36	Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond. Contraception, 2020, 101, 361-366.	0.8	113

#	Article	IF	CITATIONS
37	Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate. Contraception, 2020, 102, 168-173.	0.8	6
38	Misoprostol before to first-trimester surgical abortion: do not jump on the bandwagon, not all evidence is created equal. American Journal of Obstetrics & Gynecology MFM, 2020, 2, 100244.	1.3	0
39	Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use?. Contraception, 2019, 100, 264-268.	0.8	15
40	Bleeding patterns and endometrial safetyÂwith a 1-year, segesterone acetate/ethinyl estradiol contraceptive vaginal system. Fertility and Sterility, 2019, 112, e10-e11.	0.5	0
41	Pre-removal plasma levonorgestrel level and return ot fertility after levonorgestrel 52 mg intrauterine system discontinuation. Fertility and Sterility, 2019, 112, e306.	0.5	1
42	Medical abortion with mifepristone and vaginal misoprostol between 64 and 70â€ ⁻ days' gestation. Contraception, 2019, 100, 178-181.	0.8	20
43	Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems. Contraception, 2019, 100, 128-131.	0.8	29
44	Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System. Obstetrics and Gynecology, 2019, 133, 63-70.	1.2	34
45	Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception, 2019, 99, 323-328.	0.8	30
46	Prospective quantification of fetomaternal hemorrhage with dilation and evacuation procedures. Contraception, 2019, 99, 281-284.	0.8	4
47	Persistent free-floating pelvic trophoblastic cysts following an interstitial ectopic pregnancy. BMJ Case Reports, 2019, 12, e229732.	0.2	0
48	Mifepristone antagonization requires real studies to evaluate safety and efficacy. Contraception, 2019, 100, 427-429.	0.8	5
49	Management of early pregnancy loss with mifepristone and misoprostol: clinical predictors of success from a randomized trial. Fertility and Sterility, 2019, 112, e403.	0.5	2
50	Endometrial Safety With a 1-Year Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System [5M]. Obstetrics and Gynecology, 2019, 133, 141S-141S.	1.2	0
51	Adherence in a Phase 3 Trial of a Multipurpose Vaginal pH-Regulator vs Nonoxynol-9 [2M]. Obstetrics and Gynecology, 2019, 133, 140S-140S.	1.2	0
52	Postpartum Care for Mothers of Preterm Infants Requiring Intensive Care: A Qualitative Study [26E]. Obstetrics and Gynecology, 2019, 133, 58S-58S.	1.2	0
53	Referral Center Experience With Nonpalpable Contraceptive Implant Removals. Obstetrics and Gynecology, 2019, 134, 801-806.	1.2	17
54	Segesterone Acetate/Ethinyl Estradiol 1-Year Contraceptive Vaginal System Safety Evaluation [12M]. Obstetrics and Gynecology, 2019, 133, 143S-143S.	1.2	1

#	Article	IF	CITATIONS
55	Comparing Postpartum Visit Attendance with a Scheduled 2- to 3-Week or 6-Week Visit after Delivery. American Journal of Perinatology, 2019, 36, 936-942.	0.6	13
56	Women's preferences for permanent contraception method and willingness to be randomized for a hypothetical trial. Contraception, 2019, 99, 56-60.	0.8	11
57	Etonogestrel implant use in women primarily choosing a combined oral contraceptive pill: A proof-of-concept trial. Contraception, 2018, 97, 533-537.	0.8	5
58	More clarity needed for contraceptive mobile app Pearl Index calculations. Contraception, 2018, 97, 456.	0.8	8
59	Bleeding patterns for the Liletta [®] levonorgestrel 52 mg intrauterine system. European Journal of Contraception and Reproductive Health Care, 2018, 23, 116-120.	0.6	19
60	Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use. Contraception, 2018, 97, 210-214.	0.8	21
61	Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy. Obstetrics and Gynecology, 2018, 132, 217-218.	1.2	1
62	Return of fertility in nulliparous andÂparous women after levonorgestrel 52 mg intrauterine system discontinuation. Fertility and Sterility, 2018, 110, e46.	0.5	2
63	A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV. European Journal of Contraception and Reproductive Health Care, 2018, 23, 326-334.	0.6	16
64	Change in bleeding patterns after Liletta insertion for women with subjective baseline heavy menstrual bleeding. Contraception, 2018, 98, 350-351.	0.8	0
65	Do women want to talk about birth control at the time of a first-trimester abortion?. Contraception, 2018, 98, 535-540.	0.8	15
66	Five-Year Efficacy and Safety of the Liletta® Levonorgestrel Intrauterine System [13F]. Obstetrics and Gynecology, 2018, 131, 66S-67S.	1.2	2
67	Successful completion of total and partial salpingectomy at the time of cesarean delivery. Contraception, 2018, 98, 232-236.	0.8	13
68	Controversies in family planning: persistently elevated serum human chorionic gonadotropin levels after aspiration abortion. Contraception, 2018, 98, 541-543.	0.8	0
69	Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss. New England Journal of Medicine, 2018, 378, 2161-2170.	13.9	135
70	Interpregnancy Interval After Termination of Pregnancy and the Risks of Adverse Outcomes in Subsequent Birth. Obstetrics and Gynecology, 2017, 129, 943-944.	1.2	1
71	Naproxen Sodium for Pain Control With Intrauterine Device Insertion: A Randomized Controlled Trial. Obstetrics and Gynecology, 2017, 129, 1135-1136.	1.2	0
72	Standardizing abortion research outcomes (STAR): a protocol for developing, disseminating and implementing a core outcome set for medical and surgical abortion. Contraception, 2017, 95, 437-441.	0.8	39

#	Article	IF	CITATIONS
73	Safety outcomes of female sterilization by salpingectomy and tubal occlusion. Contraception, 2017, 95, 505-508.	0.8	19
74	Women's preferences for method of sterilization and willingness to be randomized for a theoretical trial. Contraception, 2017, 96, 303-304.	0.8	0
75	Long-Acting Reversible Contraception Initiation With a 2- to 3-Week Compared With a 6-Week Postpartum Visit. Obstetrics and Gynecology, 2017, 130, 788-794.	1.2	13
76	Quality Improvement: Changing Patterns of Antibiotic Prophylaxis for Surgical Abortion. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2017, 39, e79-e83.	0.3	0
77	Four-Year Efficacy and Safety of the Liletta® Levonorgestrel Intrauterine System [11A]. Obstetrics and Gynecology, 2017, 129, 11S-12S.	1.2	0
78	Management of Severe Range Blood Pressures During Obstetrical Care: A Quality Improvement Project [3L]. Obstetrics and Gynecology, 2017, 129, 122S-122S.	1.2	0
79	The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience. Contraception, 2017, 95, 205-210.	0.8	29
80	An updated assessment of postpartum sterilization fulfillment after vaginal delivery. Contraception, 2017, 96, 41-46.	0.8	24
81	Integrated Neurology and Family Planning Clinic to Address Gynecologic Needs of Women With Epilepsy [11N]. Obstetrics and Gynecology, 2016, 127, 117S.	1.2	0
82	Recent Trends in Incidence of Different Permanent Female Sterilization Methods [150]. Obstetrics and Gynecology, 2016, 127, 127S.	1.2	0
83	Quality Improvement. Obstetrics and Gynecology, 2016, 127, 9S.	1.2	0
84	Comparing office and telephone follow-up after medical abortion. Contraception, 2016, 94, 122-126.	0.8	23
85	Medical abortion reporting of efficacy: the MARE guidelines. Contraception, 2016, 94, 97-103.	0.8	30
86	Intrauterine Contraception. Seminars in Reproductive Medicine, 2016, 34, 175-182.	0.5	26
87	A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine systemÂplacement. American Journal of Obstetrics and Gynecology, 2016, 215, 599.e1-599.e6.	0.7	18
88	Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. European Journal of Contraception and Reproductive Health Care, 2016, 21, 361-366.	0.6	22
89	Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system. Contraception, 2016, 94, 353-356.	0.8	29
90	Factors influencing women's satisfaction with surgical abortion — reply. Contraception, 2016, 93, 373.	0.8	6

#	Article	IF	CITATIONS
91	Return of Spontaneous Menses and Fertility After Removal of the Liletta Levonorgestrel Intrauterine System [40]. Obstetrics and Gynecology, 2016, 127, 123S-124S.	1.2	1
92	Factors influencing women's satisfaction with surgical abortion. Contraception, 2016, 93, 164-169.	0.8	17
93	Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception, 2016, 93, 119-125.	0.8	9
94	Hysteroscopic Essure Inserts for PermanentÂContraception: Extended Follow-Up Results of a Phase III MulticenterÂInternational Study. Journal of Minimally Invasive Gynecology, 2016, 23, 137-138.	0.3	4
95	Rate of abnormal vaginal bleeding and contraception counseling in women undergoing chemotherapy. Journal of Community and Supportive Oncology, 2016, , 337-341.	0.1	1
96	Mifepristone With Buccal Misoprostol for Medical Abortion. Obstetrics and Gynecology, 2015, 126, 12-21.	1.2	151
97	In Reply. Obstetrics and Gynecology, 2015, 126, 1107-1108.	1.2	0
98	Removal of a Nonpalpable Etonogestrel Implant With Preprocedure Ultrasonography and Modified Vasectomy Clamp. Obstetrics and Gynecology, 2015, 126, 935-938.	1.2	20
99	Effects of a One Year Reusable Contraceptive Vaginal Ring on Vaginal Microflora and the Risk of Vaginal Infection: An Open-Label Prospective Evaluation. PLoS ONE, 2015, 10, e0134460.	1.1	34
100	Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception, 2015, 92, 10-16.	0.8	80
101	Laparoscopic Hysterectomy for Failed Labor Induction Abortion Is Neither Frugal nor Innovative. Journal of Minimally Invasive Gynecology, 2015, 22, 918.	0.3	0
102	Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. European Journal of Contraception and Reproductive Health Care, 2015, 20, 296-307.	0.6	24
103	Probability of pregnancy after sterilization: a comparison of hysteroscopic versus laparoscopic sterilization. Contraception, 2015, 91, 521.	0.8	13
104	LARC utilization based on type of medical abortion follow-up at an academic center. Contraception, 2015, 91, 403-405.	0.8	2
105	Prophylactic ibuprofen does not improve pain with IUD insertion: a randomized trial. Contraception, 2015, 91, 193-197.	0.8	49
106	Contraceptive Efficacy, Safety, Fit, and Acceptability of a Single-Size Diaphragm Developed With End-User Input. Obstetrics and Gynecology, 2015, 125, 895-903.	1.2	30
107	Acceptability of randomization to levonorgestrel versus copper intrauterine device among women requesting IUD insertion for contraception. Contraception, 2015, 92, 572-574.	0.8	3
108	Office versus telephone follow-up after medical abortion. Contraception, 2015, 92, 363.	0.8	0

#	Article	IF	CITATIONS
109	Tenth anniversary of the Society of Family Planning. Contraception, 2015, 92, 279-281.	0.8	1
110	Bleeding patterns in women using Lilettaâ,,¢, a new 52 mg levonorgestrel-releasing intrauterine system, for up to 2 years. Contraception, 2015, 92, 361-362.	0.8	1
111	Primary care physician familiarity with U.S. medical eligibility for contraceptive use. Family Medicine, 2015, 47, 15-21.	0.3	8
112	Female Tubal Sterilization. Obstetrics and Gynecology, 2014, 124, 596-599.	1.2	34
113	Understanding women's desires for contraceptive counseling at the time of first-trimester surgical abortion. Contraception, 2014, 89, 36-41.	0.8	38
114	Probability of pregnancy after sterilization: a comparison of hysteroscopic versus laparoscopic sterilization. Contraception, 2014, 90, 174-181.	0.8	34
115	Medical management of first-trimester abortion. Contraception, 2014, 89, 148-161.	0.8	49
116	Global fee prohibits postpartum provision of the most effective reversible contraceptives. Contraception, 2014, 90, 466-467.	0.8	41
117	Knowledge and practices of ulipristal acetate among faculty and residents at an academic medical center. Contraception, 2014, 90, 337.	0.8	1
118	Adherence with prescription antibiotic prophylaxis for abortions performed in the operating room. Contraception, 2014, 90, 310.	0.8	1
119	Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception, 2014, 90, 104.	0.8	4
120	Changes in genital tract immune cell populations after initiation of intrauterine contraception. American Journal of Obstetrics and Gynecology, 2014, 211, 489.e1-489.e9.	0.7	28
121	Transcervical sterilization: Population sterilization rates overestimated. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 180, 196-197.	0.5	0
122	In Reply. Obstetrics and Gynecology, 2014, 124, 1033-1034.	1.2	0
123	Effects of Age, Parity, and Device Type on Complications and Discontinuation of Intrauterine Devices. Obstetrics and Gynecology, 2014, 123, 1356.	1.2	0
124	Nomegestrol Acetate and 17β-Estradiol Reduces Menstrual Symptoms, Pain, and Cramps Compared With Drospirenone and Ethinylestradiol. Obstetrics and Gynecology, 2014, 123, 105S.	1.2	1
125	Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. Journal of Family Planning and Reproductive Health Care, 2013, 39, 156-159.	0.9	19
126	A statement on abortion by 100 professors of obstetrics: 40Âyears later. American Journal of Obstetrics and Gynecology, 2013, 209, 193-199.	0.7	21

#	Article	IF	CITATIONS
127	Types of combined oral contraceptives used by US women. Contraception, 2013, 88, 192-193.	0.8	2
128	Mifepristone vs. osmotic dilator insertion for cervical preparation prior to surgical abortion at 14–16 weeks: a randomized trial. Contraception, 2013, 87, 507-508.	0.8	1
129	Transvaginal administration of intraamniotic digoxin prior to dilation and evacuation. Contraception, 2013, 87, 76-80.	0.8	14
130	Significant Adverse Events and Outcomes After Medical Abortion. Obstetrics and Gynecology, 2013, 121, 166-171.	1.2	87
131	Toward Early Safety Alert Endpoints: Exploring Biomarkers Suggestive of Microbicide Failure. AIDS Research and Human Retroviruses, 2013, 29, 1475-1486.	0.5	16
132	Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. European Journal of Contraception and Reproductive Health Care, 2013, 18, 143-147.	0.6	18
133	Abortion, Pregnancy, and Public Health. Obstetrics and Gynecology, 2012, 119, 1273.	1.2	0
134	Abortion, Pregnancy, and Public Health. Obstetrics and Gynecology, 2012, 119, 212-214.	1.2	6
135	Federally Funded Sterilization: Time to Rethink Policy?. American Journal of Public Health, 2012, 102, 1822-1825.	1.5	27
136	Immediate versus delayed insertion of the levonorgestrel-releasing intrauterine device following dilation and evacuation: a randomized controlled trial. Contraception, 2012, 85, 240-245.	0.8	38
137	Comparison of medical abortion follow-up with serum human chorionic gonadotropin testing and in-office assessment. Contraception, 2012, 85, 402-407.	0.8	17
138	Antiabortion violence in the United States. Contraception, 2012, 86, 562-566.	0.8	8
139	Use of the CDC US medical eligibility criteria for contraceptive use among primary care physicians. Contraception, 2012, 86, 305-306.	0.8	Ο
140	Randomizing women to intrauterine device type: a pilot study experience. Contraception, 2012, 86, 318-319.	0.8	0
141	The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium. Expert Opinion on Pharmacotherapy, 2011, 12, 2403-2410.	0.9	4
142	Cervical preparation for surgical abortion between 12 and 18 weeks of gestation using vaginal misoprostol and Dilapan-S. Contraception, 2011, 83, 511-516.	0.8	19
143	Ovulation resumption after medical abortion with mifepristone and misoprostol. Contraception, 2011, 84, 230-233.	0.8	74
144	Postplacental or delayed levonorgestrel intrauterine device insertion and breast-feeding duration. Contraception, 2011, 84, 499-504.	0.8	53

#	Article	IF	CITATIONS
145	Outcomes of medical abortion through 63 days in women with twin gestations. Contraception, 2011, 84, 505-507.	0.8	10
146	The impact of out-of-pocket expense on IUD utilization among women with private insurance. Contraception, 2011, 84, e39-e42.	0.8	56
147	Racial variation in tubal sterilization rates: role of patient-level factors. Fertility and Sterility, 2011, 95, 17-22.	0.5	65
148	Immediate Versus Delayed Intrauterine Device Insertion After Uterine Aspiration. Obstetrical and Gynecological Survey, 2011, 66, 624-625.	0.2	0
149	Reliability of Laparoscopic Compared With Hysteroscopic Sterilization at 1 Year. Obstetrics and Gynecology, 2011, 118, 273-279.	1.2	27
150	Mifepristone and misoprostol for early pregnancy failure: a cohort analysis. American Journal of Obstetrics and Gynecology, 2011, 204, 386.e1-386.e6.	0.7	25
151	Immediate versus Delayed IUD Insertion after Uterine Aspiration. New England Journal of Medicine, 2011, 364, 2208-2217.	13.9	146
152	A Multi-Compartment, Single and Multiple Dose Pharmacokinetic Study of the Vaginal Candidate Microbicide 1% Tenofovir Gel. PLoS ONE, 2011, 6, e25974.	1.1	89
153	Postplacental or Delayed Insertion of the Levonorgestrel Intrauterine Device After Vaginal Delivery. Obstetrics and Gynecology, 2010, 116, 1079-1087.	1.2	150
154	Unintended Pregnancy Influences Racial Disparity in Tubal Sterilization Rates. Journal of General Internal Medicine, 2010, 25, 122-128.	1.3	39
155	Low Rates of Vasectomy Among Minorities: A Result of Differential Receipt of Counseling?. American Journal of Men's Health, 2010, 4, 243-249.	0.7	13
156	Contraceptive Efficacy, Acceptability, and Safety of C31G and Nonoxynol-9 Spermicidal Gels. Obstetrics and Gynecology, 2010, 116, 1265-1273.	1.2	30
157	Effect of a Brief Educational Intervention on the Attitudes ofÂYoung Women Toward the Intrauterine Device. Journal of Pediatric and Adolescent Gynecology, 2010, 23, 116-120.	0.3	38
158	Feasibility of telephone follow-up after medical abortion. Contraception, 2010, 81, 143-149.	0.8	94
159	A comparison of transabdominal and transvaginal ultrasonography for determination of gestational age and clinical outcomes in women undergoing early medical abortion. Contraception, 2010, 81, 240-244.	0.8	18
160	Forgettable contraception. Contraception, 2010, 81, 552-553.	0.8	0
161	Complication rates and utility of intravenous access for surgical abortion procedures from 12 to 18 weeks of gestation. Contraception, 2010, 82, 286-290.	0.8	3
162	Pain Following Post-Aspiration IUD Insertion. Contraception, 2010, 82, 189-190.	0.8	0

#	Article	IF	CITATIONS
163	Sexual function in first-time contraceptive ring and contraceptive patch users. Fertility and Sterility, 2010, 93, 21-28.	0.5	40
164	The Impact of Race and Ethnicity on Receipt of Family Planning Services in the United States. Journal of Women's Health, 2009, 18, 91-96.	1.5	78
165	"Everything I Know I Learned from My Motheror Not†Perspectives of African-American and White Women on Decisions About Tubal Sterilization. Journal of General Internal Medicine, 2009, 24, 312-319.	1.3	48
166	ORIGINAL ARTICLE: Safety Analysis of the Diaphragm in Combination with Lubricant or Acidifying Microbicide Gels: Effects on Markers of Inflammation and Innate Immunity in Cervicovaginal Fluid. American Journal of Reproductive Immunology, 2009, 61, 121-129.	1.2	19
167	Incarcerated Women and Abortion Provision: A Survey of Correctional Health Providers. Perspectives on Sexual and Reproductive Health, 2009, 41, 6-11.	0.9	30
168	Low-dose fentanyl and midazolam in outpatient surgical abortion up to 18 weeks of gestation. Contraception, 2009, 79, 122-128.	0.8	22
169	Doxycycline serum levels at the time of dilation and evacuation with two dosing regimens. Contraception, 2009, 79, 129-133.	0.8	10
170	Women's motivation to participate in contraceptive efficacy trials. Contraception, 2009, 80, 270-275.	0.8	3
171	Breastfeeding continuation among women using the levonorgestrel-releasing intrauterine device after vaginal delivery. Contraception, 2009, 80, 204-205.	0.8	1
172	Trends in tubal sterilization and intrauterine device uptake at an urban academic medical center. Contraception, 2009, 80, 205-206.	0.8	7
173	Contraception services for incarcerated women: a national survey of correctional health providers. Contraception, 2009, 80, 561-565.	0.8	38
174	Does vasectomy explain the difference in tubal sterilization rates between black and white women?. Fertility and Sterility, 2009, 91, 1642-1645.	0.5	17
175	Can We Communicate Gravidity and Parity Better?. Obstetrics and Gynecology, 2009, 113, 709-711.	1.2	20
176	Interest in Intrauterine Contraception Among Seekers of Emergency Contraception and Pregnancy Testing. Obstetrics and Gynecology, 2009, 113, 833-839.	1.2	46
177	Incarcerated women and abortion provision: a survey of correctional health providers. Perspectives on Sexual and Reproductive Health, 2009, 41, 6-11.	0.9	5
178	Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations. American Journal of Obstetrics and Gynecology, 2008, 198, 32.e1-32.e7.	0.7	7
179	Misoprostol for treatment of early pregnancy failure in women with previous uterine surgery. American Journal of Obstetrics and Gynecology, 2008, 198, 626.e1-626.e5.	0.7	25
180	Race, insurance status, and desire for tubal sterilization reversal. Fertility and Sterility, 2008, 90, 272-277.	0.5	35

#	Article	IF	CITATIONS
181	Effect of "observed start―vs. traditional "Sunday start―on hormonal contraceptive continuation rates after medical abortion. Contraception, 2008, 78, 26-30.	0.8	10
182	The prevalence of domestic violence in volunteers for abortion and contraceptive research studies. Contraception, 2008, 78, 79-83.	0.8	13
183	Baseline colposcopic findings in women entering studies on female vaginal products. Contraception, 2008, 78, 162-166.	0.8	14
184	Outcomes of medical abortion through 63 days in women with twin gestations. Contraception, 2008, 78, 168-169.	0.8	3
185	SILCS diaphragm: postcoital testing of a new single-size contraceptive device. Contraception, 2008, 78, 237-244.	0.8	42
186	Adolescent and young adult women's knowledge of and attitudes toward the intrauterine device. Contraception, 2008, 78, 211-217.	0.8	139
187	Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. Contraception, 2008, 78, 332-335.	0.8	21
188	Comparative crossover study of the PATH Woman's Condom and the FC Female Condom®. Contraception, 2008, 78, 465-473.	0.8	41
189	Multicenter Comparison of the Contraceptive Ring and Patch. Obstetrics and Gynecology, 2008, 111, 267-277.	1.2	84
190	Ultrasonographic Endometrial Thickness After Medical and Surgical Management of Early Pregnancy Failure. Obstetrics and Gynecology, 2008, 111, 106-112.	1.2	35
191	Medical Management of Early Pregnancy Failure: Efficacy. Seminars in Reproductive Medicine, 2008, 26, 411-422.	0.5	20
192	Two Distinct Oral Routes of Misoprostol in Mifepristone Medical Abortion. Obstetrics and Gynecology, 2008, 112, 1303-1310.	1.2	91
193	Six-Day Randomized Safety Trial of Intravaginal Lime Juice. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 243-250.	0.9	24
194	Mifepristone and Misoprostol Administered Simultaneously Versus 24 Hours Apart for Abortion. Obstetrics and Gynecology, 2007, 109, 885-894.	1.2	88
195	Psychiatric outcomes following medical and surgical abortion. Human Reproduction, 2007, 22, 878-884.	0.4	26
196	Contemporary Management of Early Pregnancy Failure. Clinical Obstetrics and Gynecology, 2007, 50, 67-88.	0.6	71
197	The Contraceptive Implant. Clinical Obstetrics and Gynecology, 2007, 50, 907-917.	0.6	57
198	Phase I Safety Trial of Two Vaginal Microbicide Gels (Acidform or BufferGel) Used With a Diaphragm Compared to KY Jelly Used With a Diaphragm. Sexually Transmitted Diseases, 2007, 34, 977-984.	0.8	31

#	Article	IF	CITATIONS
199	Contraceptive Effectiveness of Immediate Compared With Delayed Insertion of Intrauterine Devices After Abortion. Obstetrics and Gynecology, 2007, 109, 1286-1294.	1.2	41
200	Race, Insurance Status, and Tubal Sterilization. Obstetrics and Gynecology, 2007, 109, 94-100.	1.2	75
201	Contraceptive Efficacy of a Novel Spermicidal Microbicide Used With a Diaphragm. Obstetrics and Gynecology, 2007, 110, 577-586.	1.2	57
202	Medical management of early pregnancy failure in a patient with coronary artery disease. Fertility and Sterility, 2007, 88, 212.e1-212.e3.	0.5	5
203	Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited. Contraception, 2007, 75, 378-382.	0.8	35
204	An open-label, randomized, multi-center trial to evaluate continuation rates, side effects and acceptability of the contraceptive ring vs. the contraceptive patch in women previously using combined oral contraceptives. Contraception, 2007, 76, 157-158.	0.8	1
205	The potential of two non-vaginal routes of misoprostol administration following mifepristone for medical abortion up to 63 days gestation. Contraception, 2007, 76, 161-162.	0.8	1
206	Ability of endometrial thickness following medical abortion to predict subsequent surgical Intervention. Contraception, 2007, 76, 162.	0.8	0
207	Serum levels of doxycycline at the time of dilation and evacuation with two dosing regimens. Contraception, 2007, 76, 162.	0.8	Ο
208	Accuracy of abdominal ultrasonography in determining gestational age and outcomes in early medical abortion. Contraception, 2007, 76, 162.	0.8	0
209	Medical abortion outcomes after a second-dose of misoprostol: is the presence of cardiac motion on follow-up ultrasonography predictive of failure?. Contraception, 2007, 76, 162-163.	0.8	Ο
210	Outcome of medical abortion through 63 days in women with prior cesarean section. Contraception, 2007, 76, 163.	0.8	0
211	Misoprostol for treatment of early pregnancy failure in women with prior uterine surgery. Contraception, 2007, 76, 163.	0.8	Ο
212	Predictors of pain and bleeding in medical abortion. Contraception, 2007, 76, 163.	0.8	0
213	Predictors of dilation and curettage after medical abortion through 63 days gestation. Contraception, 2007, 76, 163-164.	0.8	Ο
214	Eliciting women's preferences in medical abortion treatment using willingness to pay. Contraception, 2007, 76, 164.	0.8	1
215	Incarcerated women and abortion provision: a survey of services in correctional health facilities. Contraception, 2007, 76, 165.	0.8	0
216	The prevalence of domestic violence in women who volunteer for gynecologic research studies. Contraception, 2007, 76, 168-169.	0.8	0

#	Article	IF	CITATIONS
217	Does vasectomy explain the difference in tubal sterilization rates between black and white women?. Contraception, 2007, 76, 173.	0.8	0
218	Race and desire for tubal sterilization reversal. Contraception, 2007, 76, 173.	0.8	2
219	Oral mifepristone and buccal misoprostol administered simultaneously for abortion: a pilot study. Contraception, 2007, 76, 215-220.	0.8	15
220	From American Idol to Plan B: a call for a shift in priorities. Contraception, 2007, 76, 337-338.	0.8	2
221	Adolescent and Young Women's Knowledge and Attitudes Toward Using Intrauterine Contraceptive Devices (IUDs). Journal of Pediatric and Adolescent Gynecology, 2007, 20, S115-S116.	0.3	2
222	Clinical indicators for success of misoprostol treatment after early pregnancy failure. International Journal of Gynecology and Obstetrics, 2007, 99, 46-51.	1.0	27
223	Enzymatic removal of asparagine-linked carbohydrate chains from heterodimer human chorionic gonadotrophin and effect on bioactivity. Reproduction, Fertility and Development, 2007, 19, 933.	0.1	3
224	Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure: results from a randomized trial. American Journal of Obstetrics and Gynecology, 2007, 196, 31.e1-31.e7.	0.7	35
225	FemCapâ,"¢ with removal strap: ease of removal, safety and acceptability. Contraception, 2006, 73, 59-64.	0.8	17
226	Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation. Contraception, 2006, 73, 440-442.	0.8	7
227	Training and attitudes about contraceptive management across primary care specialties: a survey of graduating residents. Contraception, 2006, 73, 618-622.	0.8	53
228	Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception, 2006, 74, 133-140.	0.8	84
229	Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial. Contraception, 2006, 74, 458-462.	0.8	25
230	SOGC Clinical Practice Guidelines: Ultrasound Evaluation of First Trimester Pregnancy Complications. Journal of Obstetrics and Gynaecology Canada, 2006, 28, 581.	0.3	1
231	Factors Related to Successful Misoprostol Treatment for Early Pregnancy Failure*. Obstetrics and Gynecology, 2006, 107, 73S.	1.2	0
232	Early Abortion in Ontario: Options and Costs. Journal of Obstetrics and Gynaecology Canada, 2006, 28, 504.	0.3	0
233	SILCS Diaphragm. Obstetrics and Gynecology, 2006, 107, 12S.	1.2	5
234	Progesterone Receptor Modulator for Emergency Contraception. Obstetrics and Gynecology, 2006, 108, 1089-1097.	1.2	213

#	Article	IF	CITATIONS
235	A Comparison of Medical Management with Misoprostol and Surgical Management for Early Pregnancy Failure. Obstetrical and Gynecological Survey, 2006, 61, 110-111.	0.2	1
236	Effects of Long-Term Use of Nonoxynol-9 on VaginalFlora. Obstetrics and Gynecology, 2006, 107, 136-143.	1.2	35
237	Factors Related to Successful Misoprostol Treatment for Early Pregnancy Failure. Obstetrics and Gynecology, 2006, 107, 901-907.	1.2	61
238	Post-Procedural Upper Genital Tract Infection. , 2006, , 125-139.		0
239	Mortality associated with mifepristone-misoprostol medical abortion. MedGenMed: Medscape General Medicine, 2006, 8, 26.	0.2	2
240	Oral contraceptives and breakthrough bleeding: what patients need to know. Journal of Family Practice, 2006, 55, 872-80.	0.2	4
241	Body Mass Index, Weight, and Oral Contraceptive Failure Risk. Obstetrics and Gynecology, 2005, 105, 1492.	1.2	7
242	Mifepristone in Abortion Care. Seminars in Reproductive Medicine, 2005, 23, 82-91.	0.5	13
243	The challenges of analyzing cost-effectiveness with a computer model. Fertility and Sterility, 2005, 84, 543.	0.5	0
244	The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion. Contraception, 2005, 71, 26-30.	0.8	21
245	A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. Contraception, 2005, 71, 333-336.	0.8	23
246	A pilot study of mifepristone and misoprostol administered at the same time for abortion in women with gestation from 50 to 63 days. Contraception, 2005, 71, 447-450.	0.8	25
247	Acceptability of five nonoxynol-9 spermicides. Contraception, 2005, 71, 438-442.	0.8	26
248	Lea's Shield®: colposcopic and microbiological testing during 8 weeks of use. Contraception, 2005, 72, 53-59.	0.8	2
249	How do we ensure â€~high quality' clinical research?. Contraception, 2005, 72, 83-84.	0.8	0
250	Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods. Contraception, 2005, 72, 333-336.	0.8	34
251	A Comparison of Medical Management with Misoprostol and Surgical Management for Early Pregnancy Failure. New England Journal of Medicine, 2005, 353, 761-769.	13.9	273
252	Late Sequelae of Induced Abortion. Annals of Internal Medicine, 2004, 141, 161.	2.0	0

#	Article	IF	CITATIONS
253	Participant characteristics associated with withdrawal from a large randomized trial of spermicide effectiveness. BMC Medical Research Methodology, 2004, 4, 23.	1.4	11
254	A randomized trial of saline solution–moistened misoprostol versus dry misoprostol for first-trimester pregnancy failure. American Journal of Obstetrics and Gynecology, 2004, 190, 389-394.	0.7	33
255	Prospective randomized, controlled study of postoperative pain after titanium silicone rubber clip or Silastic ring tubal occlusion. Contraception, 2004, 69, 145-150.	0.8	7
256	A phase I comparative postcoital testing study of three concentrations of C31G. Contraception, 2004, 70, 227-231.	0.8	29
257	Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study. Contraception, 2004, 70, 77-83.	0.8	27
258	Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. Contraception, 2004, 70, 313-317.	0.8	36
259	A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Contraception, 2004, 70, 233-240.	0.8	43
260	How regular is regular? An analysis of menstrual cycle regularity. Contraception, 2004, 70, 289-292.	0.8	128
261	Endometrial thickness after misoprostol use for early pregnancy failure. International Journal of Gynecology and Obstetrics, 2004, 86, 22-26.	1.0	66
262	A Randomized Comparison of Misoprostol 6 to 8 Hours Versus 24 Hours After Mifepristone for Abortion. Obstetrics and Gynecology, 2004, 103, 851-859.	1.2	93
263	Induced Abortion: An Overview for Internists. Annals of Internal Medicine, 2004, 140, 620.	2.0	34
264	Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion. American Journal of Obstetrics and Gynecology, 2003, 188, 664-669.	0.7	35
265	Miscommunication between healthcare providers and patients may result in unplanned pregnancies. Contraception, 2003, 68, 373-376.	0.8	48
266	Feasibility study of the use of a daily electronic mail reminder to improve oral contraceptive compliance. Contraception, 2003, 68, 365-371.	0.8	25
267	Pharmacoeconomics of medical abortion: a review of cost in the United States, Europe and Asia. Expert Opinion on Pharmacotherapy, 2003, 4, 503-513.	0.9	12
268	Current medical abortion care. Current Women's Health Reports, 2003, 3, 461-9.	0.2	2
269	Does Digital Vaginal Examination Using Lubricant Have an Impact on Testing for Chlamydia trachomatis by Polymerase Chain Reaction?. Sexually Transmitted Diseases, 2002, 29, 112-113.	0.8	3
270	Prospective Randomized Controlled Study of Postoperative Pain after Filshie Clip or Falope Ring. Obstetrics and Gynecology, 2002, 99, 25S-26S.	1.2	1

#	Article	IF	CITATIONS
271	The effect of extending the pill-free interval on follicular activity. Contraception, 2002, 66, 147-152.	0.8	41
272	Mifepristone and vaginal misoprostol on the same day for abortion from 50 to 63 days' gestation. Contraception, 2002, 66, 225-229.	0.8	19
273	Predicting risk of ovulation in new start oral contraceptive users. Obstetrics and Gynecology, 2002, 99, 177-182.	1.2	32
274	Medical management of missed abortion: a randomized clinical trial. Obstetrics and Gynecology, 2002, 100, 382-383.	1.2	1
275	Abortion occurred more quickly with mifepristone than methotrexate, although final success rates were similar. Evidence-Based Obstetrics and Gynecology, 2002, 4, 181-182.	0.3	0
276	Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. British Journal of Obstetrics and Gynaecology, 2001, 108, 469-473.	0.9	38
277	Mifepristone followed on the same day by vaginal misoprostol for early abortion. Contraception, 2001, 64, 87-92.	0.8	44
278	Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study. Contraception, 2001, 64, 383-391.	0.8	81
279	Mifepristone 100 mg in abortion regimens. Obstetrics and Gynecology, 2001, 98, 434-439.	1.2	26
280	Toxic shock syndrome after laminaria insertion1. Obstetrics and Gynecology, 2001, 98, 959-961.	1.2	14
281	Mifepristone 100 mg in Abortion Regimens. Obstetrics and Gynecology, 2001, 98, 434-439.	1.2	16
282	Early Pregnancy Failure—Current Management Concepts. Obstetrical and Gynecological Survey, 2001, 56, 105-113.	0.2	62
283	Toxic Shock Syndrome After Laminaria Insertion. Obstetrics and Gynecology, 2001, 98, 959-961.	1.2	6
284	Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. BJOG: an International Journal of Obstetrics and Gynaecology, 2001, 108, 469-473.	1.1	19
285	Accuracy of serum β-human chorionic gonadotropin cutoff values at 42 and 49 days' gestation. American Journal of Obstetrics and Gynecology, 2001, 185, 966-969.	0.7	7
286	The Risks of Oral Contraceptive Pills. Seminars in Reproductive Medicine, 2001, 19, 305-312.	0.5	18
287	Management of side effects and complications in medical abortion. American Journal of Obstetrics and Gynecology, 2000, 183, S65-S75.	0.7	51
288	Medical abortion regimens: Historical context and overview. American Journal of Obstetrics and Gynecology, 2000, 183, S3-S9.	0.7	56

#	Article	IF	CITATIONS
289	Alternatives to mifepristone regimens for medical abortion. American Journal of Obstetrics and Gynecology, 2000, 183, S54-S64.	0.7	20
290	Meclizine for prevention of nausea associated with use of emergency contraceptive pills: a randomized trial. Obstetrics and Gynecology, 2000, 95, 271-277.	1.2	51
291	Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. Contraception, 2000, 62, 117-124.	0.8	77
292	The efficacy of medical abortion: a meta-analysis. Contraception, 2000, 61, 29-40.	0.8	106
293	Success rates and estimation of gestational age for medical abortion vary with transvaginal ultrasonographic criteria. American Journal of Obstetrics and Gynecology, 1999, 180, 35-41.	0.7	13
294	Use of various ultrasonographic criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion. American Journal of Obstetrics and Gynecology, 1999, 181, 1419-1424.	0.7	25
295	A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception, 1999, 59, 11-16.	0.8	60
296	"pop-out―method of levonorgestrel implant removal. Contraception, 1999, 59, 383-387.	0.8	18
297	The trimonthly combination oral contraceptive regimen: is it cost effective?. Contraception, 1999, 60, 263-267.	0.8	24
298	Screening for factor V leiden mutation before prescribing combination oral contraceptives. Fertility and Sterility, 1999, 72, 646-651.	0.5	71
299	Methotrexate effects on trophoblast and the corpus luteum in early pregnancy. American Journal of Obstetrics and Gynecology, 1998, 179, 604-609.	0.7	13
300	Delayed retained products of conception after second-trimester abortion. Obstetrics and Gynecology, 1998, 92, 710.	1.2	0
301	Medical Abortion With Oral Methotrexate and Vaginal Misoprostol. Obstetrical and Gynecological Survey, 1998, 53, 25-26.	0.2	0
302	Medical treatment of ectopic pregnancy with methotrexate. Fertility and Sterility, 1997, 68, 727-730.	0.5	42
303	Effect of nonsteroidal anti-inflammatory drugs on the action of misoprostol in a regimen for early abortion. Contraception, 1997, 56, 165-168.	0.8	43
304	Medical abortion with methotrexate 75 mg intramuscularly and vaginal misoprostol. Contraception, 1997, 56, 367-371.	0.8	31
305	Medical Abortion With Oral Methotrexate and Vaginal Misoprostol. Obstetrics and Gynecology, 1997, 90, 611-616.	1.2	56
306	Misoprostol for Medical Evacuation of Early Pregnancy Failure. Obstetrics and Gynecology, 1997, 89, 768-772.	1.2	101

#	Article	IF	CITATIONS
307	Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. American Journal of Obstetrics and Gynecology, 1997, 177, 1444-1449.	0.7	24
308	Laparoscopic salpingostomy versus methotrexate injections. American Journal of Obstetrics and Gynecology, 1997, 176, 949.	0.7	0
309	Methotrexate and misoprostol for early abortion: A multicenter trial. I. Safety and efficacy. Contraception, 1996, 53, 321-327.	0.8	121
310	Oral methotrexate and vaginal misoprostol for early abortion. Contraception, 1996, 54, 15-18.	0.8	31
311	Methotrexate and misoprostol for early abortion: A multicenter trial. Acceptability. Contraception, 1996, 54, 19-22.	0.8	43
312	Laboratory criteria for menopause in women using oral contraceptives. Fertility and Sterility, 1996, 66, 101-104.	0.5	22
313	Medically induced abortion in a woman with a large myomatous uterus. American Journal of Obstetrics and Gynecology, 1996, 175, 1379-1380.	0.7	14
314	Change in serum β-human chorionic gonadotropin after abortion with methotrexate and misoprostol. American Journal of Obstetrics and Gynecology, 1996, 174, 776-778.	0.7	39
315	Acceptability of medical abortion with methotrexate and misoprostol. Contraception, 1995, 52, 41-44.	0.8	36
316	Removal of levonorgestrel capsules from the biceps muscle. International Journal of Gynecology and Obstetrics, 1995, 50, 189-191.	1.0	6
317	Laminaria versus Dilapan osmotic cervical dilators for second-trimester abortion. American Journal of Obstetrics and Gynecology, 1995, 173, 354-355.	0.7	1
318	A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. American Journal of Obstetrics and Gynecology, 1995, 173, 1578-1584.	0.7	94
319	Methotrexate and Misoprostol vs Misoprostol Alone for Early Abortion. JAMA - Journal of the American Medical Association, 1994, 272, 1190.	3.8	64
320	Methotrexate and misoprostol for abortion at 57–63 days gestation. Contraception, 1994, 50, 511-515.	0.8	30
321	Methotrexate and misoprostol for early abortion. Contraception, 1993, 48, 339-348.	0.8	115
322	Methotrexate for abortion at ≤2 days gestation. Contraception, 1993, 48, 519-525.	0.8	36
323	Cost of ectopic pregnancy management: surgery versus methotrexate*â€*Supported by grant number HS07373–01 from the Agency for Health Care Policy and Research.â€Reprints not available Fertility and Sterility, 1993, 60, 963-969.	0.5	68
324	Comparison of endometrial biopsy and urinary pregnanediol glucuronide concentration in the diagnosis of luteal phase defect **Presented in part at the 35th Annual Meeting of the Society for Gynecologic Investigation, Baltimore, Maryland, March 17 to 20, 1988 Fertility and Sterility, 1990, 54, 1008-1011.	0.5	11

#	Article	IF	CITATIONS
325	The Northwestern University triplet study. American Journal of Obstetrics and Gynecology, 1988, 159, 1140-1143.	0.7	0
326	Contraception and Surgical Abortion Aftercare. , 0, , 208-223.		1
327	Ensuring Quality Care in Abortion Services. , 0, , 335-351.		0
328	Multifetal Pregnancy Reduction and Selective Termination. , 0, , 312-318.		5
329	Unintended Pregnancy and Abortion in the USA: Epidemiology and Public Health Impact. , 0, , 24-35.		3
330	Pregnancy Loss. , 0, , 264-279.		1
331	Abortion for Fetal Abnormalities or Maternal Conditions. , 0, , 302-311.		2
332	Providing Abortion in Low-Resource Settings. , 0, , 319-334.		1
333	Abortion Law and Policy in the USA. , 0, , 36-47.		1
334	Medical Evaluation and Management. , 0, , 78-89.		2
335	Clinical Assessment and Ultrasound in Early Pregnancy. , 0, , 63-77.		1
336	The Challenging Abortion. , 0, , 193-207.		4
337	Unsafe Abortion: The Global Public Health Challenge. , 0, , 10-23.		1
338	Abortion and Medicine: A Sociopolitical History. , 0, , 1-9.		8
339	Answering Questions About Long-Term Outcomes. , 0, , 252-263.		0
340	Surgical Complications: Prevention and Management. , 0, , 224-251.		5
341	Medical Methods to Induce Abortion in the Second Trimester. , 0, , 178-192.		6

#	Article	IF	CITATIONS
343	Medical Abortion in Early Pregnancy. , 0, , 111-134.		10
344	Appendix: Resources for Abortion Providers. , 0, , 352-368.		1
345	Dilation and Evacuation. , 0, , 157-177.		8